Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Novel anticonvulsant approved by FDA

Dec. 31, 1996

Japanese researchers describe analgesic tripeptides

Dec. 31, 1996

First phase II results for Innapharma's peptide antidepressant

Dec. 30, 1996

New agents for CNS disorders claimed by HHS

Dec. 30, 1996

Copaxone approved by FDA

Dec. 24, 1996

AACTG begins phase II memantine trial

Dec. 24, 1996

T Cell Sciences reports progress on TCAR program

Dec. 24, 1996

Otsuka describes new analgesics

Dec. 24, 1996

Neuroprotective polypeptide reported by Amgen

Dec. 24, 1996

Algos and Interneuron codevelop novel antimigraine combination

Dec. 23, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...